Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

BACKGROUND: Previous results from an interim analysis of an open-label, randomized, phase 3 study demonstrated that bortezomib combined with pegylated liposomal doxorubicin (PLD) was superior to bortezomib monotherapy in patients with relapsed/refractory multiple myeloma who had previously received...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Orlowski, Robert Z., Nagler, Arnon, Sonneveld, Pieter, Bladé, Joan, Hajek, Roman, Spencer, Andrew, Robak, Tadeusz, Dmoszynska, Anna, Horvath, Noemi, Spicka, Ivan, Sutherland, Heather J., Suvorov, Alexander N., Xiu, Liang, Cakana, Andrew, Parekh, Trilok, San-Miguel, Jesús F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5701574/
https://ncbi.nlm.nih.gov/pubmed/27191689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30026
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados